Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4529]

SABCS 2015: Promising phase 1 results lead to phase 2 for ONT-380 in HER2 breast cancer

SABCS 2015: Promising phase 1 results lead to phase 2 for ONT-380 in HER2 breast cancer

Monoclonal antibody increases disease-free survival in breast cancer

Monoclonal antibody increases disease-free survival in breast cancer

Five out of six women at higher risk reject drugs to prevent breast cancer

Five out of six women at higher risk reject drugs to prevent breast cancer

ASH 2015: Blinatumomab data shows benefit in Phase 2 trial in ALL patients with persistent or recurrent minimal residual disease

ASH 2015: Blinatumomab data shows benefit in Phase 2 trial in ALL patients with persistent or recurrent minimal...

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia...

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic...

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment...

More from ecancer